NKGen Biotech Common StockNASDAQ: NKGN

SANTA ANA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen Biotech, will present details on their cryopreserved allogeneic NK cell therapy platform as well as updated Phase 1 data on its use in solid tumors without lymphodepletion at the 6th Annual Allogeneic Cell Therapies Summit to be held in Boston, MA, from June 10-12, 2024.

SNK02 has the potential to be a first-in-class cryopreserved allogeneic NK cell therapy for solid tumors that does not require lymphodepletion before administration, which may lead to better overall synergy in future combination regimens with immune checkpoint inhibitors.

NKGen Biotech (NASDAQ: NKGN ) stock is taking off on Monday after the clinical-stage biotechnology company got an update on its Phase 2 clinical trial. The company says that its Safety Review Committee has given it the go-ahead to start its Phase 2 clinical study of SNK01.

SNK01, a cryopreserved, autologous enhanced natural killer cell therapy, delivered in highest dose to date, demonstrates preliminary clinical benefit without any drug-related adverse events.

SANTA ANA, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a biotechnology company in the clinical stage, focusing on developing and selling innovative autologous, allogeneic, and CAR-NK natural killer (“NK”) cell therapies, has announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen, will be presenting key features of the Company's cryopreserved, autologous, non-genetically modified NK cell therapy product, SNK01. This product has shown increased cytotoxicity and activating receptor expression for treating neurodegenerative diseases and solid tumors. The presentation will take place at the 5th International Cell & Gene Therapy China Summit & Exhibition (CGCS) in Nanjing, China, from May 22–24, 2024.

NKGen Biotech (NASDAQ: NKGN ) stock is soaring higher on Wednesday alongside heavy pre-market trading of the clinical-stage biotechnology company's shares. This has more than 6 million shares of NKGN stock changing hands as of this writing.